MTOR and prostate carcinoma: Since autophagy has been considered as a novel mechanism for CRPC cells to evade enzalutamide treatment46 and metformin can inhibit autophagy in prostate cancer cells via AMPK/mTOR signaling pathway, it is worthy to explore the effect of metformin along this axis.